Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online November 14, 2007
Diabetes 57:387-394, 2008
DOI: 10.2337/db07-1309
© 2008 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-1309v1
57/2/387    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, A. P.
Right arrow Articles by Lira, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, A. P.
Right arrow Articles by Lira, S. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Islet Expression of M3 Uncovers a Key Role for Chemokines in the Development and Recruitment of Diabetogenic Cells in NOD Mice

Andrea P. Martin1, Marcos G. Grisotto1, Claudia Canasto-Chibuque1, Steven L. Kunkel2, Jonathan S. Bromberg1,3,4, Glaucia C. Furtado1, and Sergio A. Lira1

1 Immunology Institute, Mount Sinai School of Medicine, New York, New York
2 Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
3 Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York
4 Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York

Address correspondence and reprint requests to Dr. Sergio A. Lira, Immunology Institute, Mount Sinai School of Medicine, 1425 Madison Ave., Box 1630, New York, NY 10029-6574. E-mail: sergio.lira{at}mssm.edu

Abbreviations: CFSE, carboxyfluoroscein succinimidyl ester; HBSS, Hanks’ balanced salt solution; MHV68, mouse herpesvirus 68; PNAd, peripheral lymph node addressin; PPLN, peripancreatic lymph node; RIP, rat insulin promoter; TCR, T-cell receptor


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
OBJECTIVE—Type 1 diabetes is an autoimmune disease characterized by a local inflammatory reaction in and around islets followed by selective destruction of insulin-secreting β-cells. We tested the hypothesis that chemokines affect different mechanisms responsible for the development of diabetes in NOD mice.

RESEARCH DESIGN AND METHODS—We examined chemokine expression in islets of NOD mice and tested their functional relevance to development of diabetes using transgenic mice expressing the mouse herpesvirus 68–encoded chemokine decoy receptor M3 (NOD-M3 mice) in insulin-secreting β-cells.

RESULTS—Multiple chemokines were expressed in pancreatic islets of NOD mice before development of diabetes. Islet-specific expression of the pan-chemokine inhibitor M3 dramatically reduced leukocyte infiltration and islet destruction and completely blocked development of diabetes in NOD-M3 mice. M3 blocked diabetes by inhibiting the priming of diabetogenic cells in the pancreatic lymph nodes and their recruitment into the islets. This effect was specific to the pancreatic islets because M3 expression did not affect other ongoing autoimmune processes.

CONCLUSIONS—These results demonstrate that chemokines mediate afferent and efferent immunity in type 1 diabetes and suggest that broad chemokine blockade may represent a viable strategy to prevent insulitis and islet destruction.

Type 1 diabetes is an autoimmune disease characterized by a local inflammatory reaction in and around islets followed by selective destruction of insulin-secreting β-cells (1). The factors leading to the destruction of the islets are still unknown, but it is thought that immune-based mechanisms are responsible for the death of the β-cells (2). T-cells are critical in the pathogenesis of diabetes. Transfer of T-cells isolated from diabetic NOD mice into irradiated NOD recipients leads to diabetes (3). Furthermore, NOD-nu/nu mice that lack the thymus do not develop insulitis or diabetes (4). Other studies support a role for macrophages in induction of diabetes. Depletion of macrophages with clodronate-loaded liposomes leads to disappearance of dendritic cells, macrophages, and lymphocytes from the endocrine pancreas of NOD mice and causes a delay in the onset of diabetes (5). Moreover, macrophage depletion affects development of β-cell–cytotoxic T-cells and prevents autoimmune diabetes (6).

Several lines of evidence suggest a role for chemokines in the pathogenesis of diabetes. Chemokines are found in freshly isolated islets or are produced by cultured pancreatic β-cells, including CCL5, CXCL9, CXCL10 (7,8), and CCL2 (7,9). CCL2 expression in the pancreas also parallels disease progression in NOD mice (10,11). CCL21 is not expressed by pancreatic islets normally, but it has been observed in the pancreas of NOD mice (12) and may be an important factor contributing to autoimmunity (13). Animals lacking the chemokine receptor for CXCL10, CXCR3, show delayed onset of diabetes subsequent to a viral infection (7). Also, antibody neutralization of the macrophage-derived chemokine CCL22 causes a significant reduction of CCR4+ T-cells within the pancreatic infiltrates and attenuates disease onset and insulitis frequency in an adoptive transfer model (14). In addition to a role in recruitment of pathogenic T-cells (14,15), chemokines have been implicated in recruitment of regulatory CD4+CD25+ T-cells to the pancreatic islets (16). However, despite suggestive evidence that chemokines are expressed during conditions leading to diabetes, there are no studies to date that conclusively demonstrate that chemokine blockade prevents diabetes.

Here, we show that several chemokines are expressed before development of diabetes and that islet-specific expression of the pan-chemokine blocker M3 abrogates inflammatory cell infiltration of the islets and completely blocks development of diabetes in NOD mice.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
NOD and NOD.SCID mice were obtained from The Jackson Laboratories (Bar Harbor, ME). Rat insulin promoter (RIP)-M3 mice, described previously (17), were backcrossed from a mixed B6D2 (C57Bl/6 x DBA/2) background onto the NOD background for 11 generations and onto B6 background for >11 generations. BDC2.5 NOD mice were provided by Dr. Ralph Steinman (The Rockefeller University, New York). In all experiments, transgenic mice were compared with their corresponding littermates. All mice were housed under specific pathogen-free conditions in individually ventilated cages at the Mount Sinai School of Medicine Animal Facility. All experiments were performed following institutional guidelines.

Diabetes.
The blood glucose was monitored weekly using a one-touch blood Ascensia Elite XL glucometer (Bayer, Elkhart, IN). Animals were considered diabetic when their blood glucose levels were >250 mg/dl in two consecutive daily measurements.

Histology.
For immunohistochemical staining, slides were incubated for 1 h at room temperature with purified primary antibodies followed by incubation with the appropriate labeled secondary antibodies for 30 min. Primary antibodies used were anti-CD45, CD3, CD31, CD11c, B220, CD11b from BD Biosciences Pharmigen (San Diego, CA); F4/80 from Serotec; anti-CCL1, anti-CCL21, anti-CCL2, and rat anti-insulin from R&D Systems (Minneapolis, MN); rabbit anti-CXCL9 (provided by J. Farber [National Institutes of Health, Rockville, MD]); anti-CCL3, -CCL4, -CCL11, -CCL22, and -CXCL10 (provided by S. Kunkel); and guinea pig polyclonal anti-insulin from DAKOCytomation (Carpinteria, CA). Secondary antibodies used were Alexa Fluor 488–and Alexa Fluor 594–goat anti-rat IgG from Molecular Probes (Eugene, OR) and Cy3-goat anti-Armenian hamster, fluorescein isothiocyanate-donkey anti–guinea pig IgG, and Cy5-goat anti-rat from Jackson ImmunoResearch (West Grove, PA).

To determine the degree of islet infiltration in NOD and NOD-M3 female mice and in NOD.SCID mice in transfer experiments, groups of mice were analyzed at 10 or 30 weeks of age or 9 weeks after transfer, respectively, assessing at least 80–100 islets per animal. Insulitis was scored as follows: grade 0, no lesions; grade 1, peri-insular leukocytic aggregates, usually periductal infiltrates; grade 2, <25% islet destruction; and grade 3, >25% islet destruction. An insulitis score for each mouse was obtained by dividing the total score for each pancreas by the number of islets examined. Data are presented as mean insulitis score ± SD for the indicated experimental groups.

Isolation of pancreatic islets of Langerhans.
Islets of Langerhans were isolated as previously described (18). Briefly, the common bile duct was clamped distal to the pancreatic duct junction at its hepatic insertion. The proximal common bile duct was then cannulated using a 27-gauge needle, and the pancreas was infused by retrograde injection of 2 ml ice-cold collagenase-V solution (1 mg/ml; Sigma, St. Louis, MO) in Hanks’ balanced salt solution (HBSS). Pancreatic tissue was recovered and subjected to a 15-min digestion at 37°C. Ice-cold HBSS was added, and the suspension was vortexed at full speed for 10 s. Islets were hand-picked under a dissecting microscope.

Flow cytometry analysis.
Isolated islets or lymph nodes were incubated in 5 mg/ml collagenase D (Roche Applied Science, Indianapolis, IN) at 37°C for 45 min. Samples were strained through a 70-µm diameter nylon mesh to obtain a single-cell suspension, centrifuged, and washed in PBS. All cell suspensions were resuspended in FACS staining buffer (PBS containing 2% fetal calf serum and 0.01% sodium azide). Islet suspension cells were incubated for 20 min at 4°C with 5 µg/ml Fc block (BD PharMingen, San Diego, CA) and then stained with directly conjugated primary monoclonal antibodies (BD PharMingen). Samples were analyzed in a FACSCanto instrument (Becton Dickinson, San Jose, CA). Data were analyzed using the FlowJo software (Tree Star).

Adoptive transfer studies.
Splenocytes (20 x 106 cells) obtained from newly diabetic NOD female mice were injected intravenously into 5- to 6-week-old NOD.SCID and NOD-M3.SCID mice. In other experiments, splenocytes (20 x 106 cells) obtained from diabetic NOD and nondiabetic NOD-M3 female mice were injected intravenously into 5- to 6-week-old NOD.SCID mice. BDC2.5 (6–11 weeks of age) splenocytes (5 x 107) were incubated with 10 mmol/l carboxyfluoroscein succinimidyl ester (CFSE) for 10 min at 37°C. The reaction was quenched with 10 ml cold PBS and followed by washing twice in PBS. The 2.5 x 107 CFSE-labeled total splenocytes in 100 µl sterile PBS were injected intravenously per recipient (4- to 6-week-old NOD and NRM3 mice). At day 4 after transfer, peripancreatic and cervical lymph nodes were removed, and a single cell suspension was done per each lymph node and each recipient mouse. For monitoring the extent of cell death in the adoptively transferred cells, lymph node cells from the recipients were also stained for PI, CD3, CD4, and Vβ4 antibodies (BD Biosciences Pharmigen).

Statistical analysis.
One-way ANOVA and unpaired t-test were used to determine statistical significance. Differences were considered significant when P < 0.05.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
NOD islets express several chemokines.
In NOD mice, infiltration of mononuclear cells into pancreatic islets begins as early as 4–6 weeks of age, accumulating in the periphery (peri-insulitis) of a few pancreatic islets (19). The autoimmune destruction of the islets is extensive by 10 weeks of age, 8–12 weeks before the onset of overt diabetes (20,21). To analyze the expression of chemokines in islets of NOD female mice, we performed immunostaining using antibodies against CXCL9, CXCL10, CCL1, CCL3, CCL4, CCL22, and CCL24; insulin; CD31; and CD45. By 4–6 weeks of age (n = 5), the islets of Langerhans had a small number of CD45+ cells that localized to the periphery of the islets (Fig. 1A and B). All chemokines studied were expressed in islets with peri-insulitis. CCL1, CCL3, CCL4, CCL22, CXCL9, and CXCL10 were primarily expressed by infiltrating cells (Fig. 1C, D, E, G, I, and J, respectively). CXCL10 was also expressed by β-cells (Fig. 1J), in agreement with a previous study (22). CCL24 was expressed by infiltrating cells (Fig. 1H) and by CD31+ endothelial cells in the islets (Supplemental Fig. 1, which is detailed in the online appendix [available at http://dx.doi.org/10.2337/db07-1309]). As described previously (12), CCL21 was expressed in paraductal areas, and its expression was increased in areas rich in inflammatory cells (Fig. 1F). Analysis of pancreata of 10-week-old mice (n = 5) showed increased in the expression of all chemokines studied compared with the earlier time points (data not shown). At this point, large infiltrates occupying the whole islet were observed. Some of these aggregates had T- and B-cells (Fig. 1K) and peripheral lymph node addressin (PNAd)–positive high endothelial vessels that coexpressed CXCL9 (Fig. 1L). Taken together, these results show that numerous chemokines are expressed in NOD islets and suggest that the expression of several chemokines may be necessary to drive the recruitment of inflammatory cells required for the development of diabetes.


Figure 1
View larger version (103K):
[in this window]
[in a new window]

  		FIG. 1. Expression of chemokines in islets of Langerhans in NOD mice. Immunostaining for insulin (green) and CD45 (A and B), CCL1 (C), CCL3 (D), CCL4 (E), CCL21 (F), CCL22 (G), CCL24 (H), CXCL9 (I), and CXCL10 (J) (red) was performed in pancreata from NOD mice at 4–6 weeks of age. Note that chemokine expression is mostly associated with the inflammatory cells. K: Pancreata from NOD mice at 10 weeks of age shows a significant infiltrate formed by T-cells (CD3, red) and B-cells (B220, blue) and presence of PNAd+ cells (green). L: CXCL9 is expressed by the PNAd+ cells. Scale bars = 100 µm. (Please see http://dx.doi.org/10.2337/db07-1309 for a high-quality digital representation of this figure.)

 
Expression of M3 in NOD islets prevents development of insulitis and diabetes.
To examine whether chemokine blockade would affect diabetes development in NOD mice, we backcrossed mice expressing M3, a viral chemokine binding protein, in β-cells (17) onto the NOD background. N11 female NOD-M3 and their NOD littermates were monitored weekly for the development of hyperglycemia. By 45 weeks of age, >80% of the NOD female mice (n = 61) were diabetic (Fig. 2A). Remarkably, expression of M3 in islets of NOD mice (NOD-M3 littermates, n = 66) completely abrogated the development of diabetes (Fig. 2A, P < 0.0001). Furthermore, NOD-M3 mice did not develop disease over the next 15 weeks (n = 16, Fig. 2A).


Figure 2
View larger version (60K):
[in this window]
[in a new window]

  		FIG. 2. Expression of M3 in β-cells of NOD mice blocks development of diabetes but not autoimmunity against salivary glands. A: Cumulative incidence of diabetes in NOD nontransgenic littermates (n = 61) and NOD-M3 (n = 66) mice until 45 weeks of age and NOD-M3 (n = 16) mice until 60 weeks of age. Representative picture of immunostaining for CD45 (red) and insulin (green) in pancreata from nontransgenic littermates (B) and NOD-M3 (C) mice at 10 weeks of age. D: Insulitis score of pancreata from NOD and NOD-M3 mice, 10 weeks of age (n = 5/group). Representative picture of immunostaining for CD45 (red) in salivary glands from nontransgenic littermates (E) and NOD-M3 (F) mice at 10 weeks of age. Scale bars = 250 µm. (Please see http://dx.doi.org/10.2337/db07-1309 for a high-quality digital representation of this figure.)

 
To investigate the effect of M3 expression by β-cells on insulitis, we examined pancreata from NOD and NOD-M3 female mice at 10 weeks of age (n = 5/group). Semiquantitative analysis of islet infiltrates showed that, as expected, most (95%) islets from NOD nondiabetic mice had peri-insulitis and in some cases developed a destructive inflammatory infiltrate (Fig. 2B and D), with marked loss of β-cell mass. In contrast, islets from NOD-M3 mice were virtually devoid of infiltrating cells and showed a normal complement of insulin-producing cells (Fig. 2C and D, P = 0.004). None of the NOD-M3 females that were more than 60 weeks of age (n = 13) showed insulitis. Only 12 ± 10% of islets had peri-insulitis, and in some cases, inflammatory cells were present in the exocrine tissue (Supplemental Fig. 2).

Lymphocytes are often observed in the salivary and lacrimal glands of NOD mice (23). We analyzed the presence of infiltrates in salivary and lacrimal glands from NOD and NOD-M3 mice at 10 weeks of age and onward. CD45+ infiltrates were found in salivary glands of both NOD (20 of 20) and NOD-M3 (22 of 22) mice (Fig. 2E and F, respectively). Small infiltrates were also found in lacrimal glands of NOD (3 of 5) and NOD-M3 (2 of 5) mice. Overall, these findings indicate that β-cell expression of M3 prevented islet mononuclear infiltration and diabetes development but did not prevent cellular infiltration into other organs.

Expression of M3 in pancreas impedes infiltration of diabetogenic cells into the islets.
Because the absence of mononuclear cells in the pancreas of NOD-M3 mice could be due to a blockade of tissue accumulation of diabetogenic cells, we tested whether M3 blocked entry of diabetogenic cells into the islets. To generate mice deficient in mature T- and B-cells that also expressed M3 in islets, we crossed NOD-M3 mice to NOD.SCID mice (referred as NOD-M3.SCID mice). When splenocytes from newly diabetic NOD females were transferred into young NOD.SCID mice, all NOD.SCID mice (9 of 9) developed diabetes within 7 weeks of transfer (Fig. 3A). Although autoreactive T-cells within NOD splenocytes could also induce diabetes in all NOD-M3.SCID recipient mice (11 of 11) (Fig. 3A), the development of diabetes was significantly delayed (P = 0.0086). To test whether the delay in diabetes development was caused by a reduced influx of the cells into the islets, we examined pancreata of the recipients 2 weeks after transfer. NOD.SCID recipients had insulitis and peri-insulitis in 75% islets (Fig. 3B and D). In contrast, NOD-M3.SCID mice (n = 5) had mild infiltrates of leukocytes in ~25% of the islets and a normal complement of insulin-producing cells (Fig. 3C and D). However, at later time points, infiltrates in islets from NOD-M3.SCID mice were comparable with those observed in NOD.SCID recipients (data not shown). These results indicate that M3 expression delayed the insulitis and islet destruction induced by diabetogenic splenocytes derived from NOD mice.


Figure 3
View larger version (44K):
[in this window]
[in a new window]

  		FIG. 3. Islet-specific expression of M3 delays migration of diabetogenic cells into the islets and impairs their development. A: Cumulative incidence of diabetes in NOD.SCID (n = 9) and NOD-M3.SCID (n = 11) recipients of splenocytes from diabetic NOD mice. Representative picture of immunostaining for CD45 (red) and insulin (green) in pancreata from NOD.SCID (B) and NOD-M3.SCID (C) recipients of splenocytes from diabetic NOD mice 14 days after transfer. D: Insulitis score of pancreata from NOD.SCID and NOD-M3.SCID recipients of splenocytes from diabetic NOD mice 14 days after transfer (n = 5/group). E: Cumulative incidence of diabetes in NOD.SCID recipients of splenocytes from diabetic NOD (n = 7) and NOD-M3 (n = 19) mice. Representative picture of immunostaining for CD45 (red) and insulin (green) in pancreata from NOD.SCID recipients of splenocytes from NOD (F) and NOD-M3 (G) mice 16 weeks after transfer. H: Insulitis score of pancreata from NOD.SCID recipients of splenocytes from NOD (n = 7) and NOD-M3 (n = 19) mice 16 weeks after transfer. Scale bars = 250 µm. (Please see http://dx.doi.org/10.2337/db07-1309 for a high-quality digital representation of this figure.)

 
Because M3 expression in the islets delayed but did not completely prevent diabetes after transfer of diabetogenic cells, we considered the possibility that M3 expression also inhibited development of diabetogenic cells in NOD-M3 mice. To determine whether functional diabetogenic splenocytes could be detected in NOD-M3 mice, we harvested spleen cells from NOD and NOD-M3 mice and transferred them into young NOD.SCID female mice. After transfer of NOD splenocytes, all NOD.SCID recipients (n = 7) became diabetic in 8 weeks. No diabetes was observed in the recipients (n = 19) up to 16 weeks after transfer of splenocytes from NOD-M3 mice (Fig. 3E). Histological analyses of the pancreata from the recipients showed that 100% the islets of the animals transferred with splenocytes from NOD mice had massive cellular infiltration and few remaining insulin-producing cells (Fig. 3F and H). Animals that received NOD-M3 splenocytes had diffuse, low-grade infiltrates of leukocytes in the islets and a normal complement of insulin-producing cells (Fig. 3G and H). Interestingly, most of the NOD.SCID mice that received NOD-M3 splenocytes had infiltration in the islets but only in 60% of them. Furthermore, these infiltrates were less severe than those observed in recipients of NOD cells (Fig. 3H). Lymphocytic infiltrates consisting mainly of CD3+ T-cells and B220+ B-cells were present in the salivary glands of NOD.SCID mice transplanted with both splenocytes from NOD and NOD-M3 mice (Supplemental Fig. 3A and B), suggesting that the presence of M3 blocked development of diabetogenic cells but did not affect autoimmune disease to salivary glands. Taken together, these results indicate that islet-specific expression of M3 delays insulitis induced by adoptively transferred NOD splenocytes and impairs the development of diabetogenic cells.

Expression of M3 in pancreas reduces local inflammation that leads to a defective generation of diabetogenic cells.
The initiating events in diabetes are not fully understood, but β-cell stress and death during early islet restructuring are thought to provide autoantigens, which induce the formation of diabetogenic cells in peripancreatic lymph nodes (PPLNs) (24,25). Therefore, we asked whether expansion of islet-specific CD4+ T-cells was affected in NOD-M3 mice. To this end, we took advantage of BDC2.5 NOD T-cell receptor (TCR)-transgenic mice, which carry the rearranged TCR-{alpha} (V{alpha}1) and -β (Vβ4) chain genes from a diabetogenic, β-cell–specific, CD4+ T-cell clone isolated from a diabetic NOD mouse (26). Adoptively transferred CFSE-labeled naive BDC2.5 splenocytes were analyzed for their proliferation in PPLNs and irrelevant cervical lymph nodes on the basis of CFSE dilution on day 4 after transfer into NOD and NOD-M3 recipients. BDC2.5 cells showed significantly lower levels of proliferation in PPLNs of NOD-M3 recipients (13 ± 6% n = 12; Fig. 4A, bottom right panel), whereas NOD recipients displayed a significantly higher (P < 0.0001) percentage of proliferating BDC2.5 T-cells (35 ± 11% n = 8; Fig. 4A, bottom left panel). BDC2.5 cells did not proliferate in cervical lymph nodes from NOD and NOD-M3 recipients (Fig. 4A, top panel).


Figure 4
View larger version (41K):
[in this window]
[in a new window]

  		FIG. 4. Expression of M3 in pancreas reduces local inflammation that leads to defective generation of diabetogenic cells. A: Proliferation profiles of CFSE-labeled BDC2.5 (Vβ4+CD4+) T-cells recovered 4 days after transfer from cervical lymph nodes and PPLNs of 4-week-old NOD (n = 7) and NOD-M3 (n = 12) mice. Representative plots from four separate experiments are shown. The CFSE profile of Vβ4+CD4+ T-cells in NOD and NOD-M3 recipients is represented in the left and right, respectively. B and C: Dendritic cell subsets in PPLNs of 30- to 40-day-old NOD (n = 7) and NOD-M3 (n = 8) mice. Values indicate the relative (B) or absolute number (C) of each subset (analysis was performed in alive [PI–] cells; average ± SD of three independent experiments, *P = 0.02; **P = 0.0011). D: Representative dot-plot of the analysis performed in islets isolated from NOD and NOD-M3 mice stained with anti-CD11c (x-axis) and CD11b (y-axis) antibodies. Cells were gated in PI–/CD45+ cells. E and F: Dendritic cell subsets in isolated islets from 4- to 5-week-old NOD (n = 8) and NOD-M3 (n = 9) mice. Values indicate the relative (E) or absolute number (F) of each subset (analysis was performed in alive [PI–] cells, CD45+ cells; average ± SD of three independent experiments, **P = 0.0054; ***P < 0.0001). Absolute number of cell subsets in isolated islets represents the absolute number of cells per 100 islets.

 
Dendritic cells are believed to be essential in the initial activation of islet-specific T-cells in PPLNs (27). Because islet-specific BDC2.5 cells CD4+ T-cells proliferated less when transferred into NOD-M3 mice, it could be argued that the observed differences could be due to alterations in the number of dendritic cells in PPLNs. To test this hypothesis, we compared the composition of dendritic cell subsets in PPLNs from 30- to 40-day-old NOD (n = 7) and NOD-M3 (n = 8) mice. To investigate the different dendritic cell subsets, single cell suspensions were stained with anti-CD11c and CD11b antibodies and analyzed by flow cytometry. We observed that the relative number of CD11c+CD11b+ cells in PPLNs from NOD-M3 mice was reduced compared with that in NOD mice (0.48 ± 0.08% in NOD mice vs. 0.3 ± 0.02% in NOD-M3 mice, P = 0.02; Fig. 4B). This difference was more evident when we analyzed the absolute number of CD11c+CD11b+ dendritic cells (4.5 ± 1.5 x 103 cells in NOD mice vs. 2.1 ± 0.6 x 103 cells in NOD-M3 mice, P = 0.0011; Fig. 4C). The relative and absolute numbers of the other two populations (CD11c+CD11b– and CD11c–CD11b+ cells) were not affected (Fig. 4B and C). There were no differences among these cell subsets in cervical lymph nodes (Supplemental Fig. 4A and B). Because dendritic cells capture antigen in tissues and then migrate into draining lymph nodes to present their antigens to T-cells, we asked whether the presence of M3 in the islets would alter the composition of dendritic cells present in the islets. We isolated islets from NOD and NOD-M3 mice and stained single cell suspensions with different surface markers. As shown in Fig. 4D–F, we observed a significant reduction in the relative number of CD11c+CD11b+ cells in islets of NOD-M3 mice (22.9 ± 3.4% in NOD mice vs. 11.1 ± 1.5% in NOD-M3 mice; P = 0.0054 Fig. 4E) and in the absolute number of this dendritic cell subset (Fig. 4F). NOD-M3 249 ± 47 CD11c+CD11b+ cells/100 islets, whereas the number of CD11c+CD11b+ cells from islets of NOD mice was increased fourfold (965 ± 85 cells/100 islets) (P < 0.0001; Fig. 4F). Interestingly, there was no difference in the number of CD11c+CD11b+ cells in the blood of NOD-M3 mice when we compared with blood of NOD mice (Supplemental Fig. 4C). To investigate whether this difference was driven solely by the expression of M3, we measured the number of CD11c+CD11b+ cells in islets of mice that are not prone to autoimmunity. To this end, we isolated islets from B6 and 6RIP-M3 mice (RIP-M3 mice (17) crossed over 10 times into the B6 background). We found that the expression of M3 in a nonautoimmune background does not alter the relative or the absolute numbers (Fig. 5A and B) of any dendritic cell subset analyzed. Taken together, these results indicate that M3 expression by β-cells in NOD mice decreases inflammation in the islets, impairs the migration of a subset of dendritic cells into the islets and PPLNs, and reduces the proliferation of diabetogenic cells in the draining lymph nodes.


Figure 5
View larger version (16K):
[in this window]
[in a new window]

  		FIG. 5. Dendritic cell subsets are similar in islets isolated from B6 and RIP-M3 mice. A and B: Dendritic cell subsets in islets isolated from 4- to 8-week-old B6 (n = 5) and 6RIP-M3 (n = 6) mice. Values indicate the relative (A) or absolute number (B) of each subset (analysis was performed in alive [PI–], CD45+ cells; average ± SD of three independent experiments). Absolute number of cell subsets in isolated islets represents the absolute number of cells per 100 islets.

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we examined the role of the chemokine system in an experimental model of diabetes. We show that chemokine expression precedes development of diabetes and that islet-specific blockade of chemokine function reduces the local inflammation that results in a defective development and pancreatic accumulation of diabetogenic cells. These results thus constitute formal demonstration that chemokines are critical determinants of autoimmune diabetes.

A pattern of multiple chemokine expression is found in the islets of NOD mice before disease. Our results confirm and expand results obtained by other groups (12,22,28). Prediabetic NOD islets expressed inflammatory (CCL1, CCL3, CCL4, CCL22, CCL24, CXCL9, and CXCL10) as well as homeostatic chemokines (CCL21). The expression of all chemokines was closely associated, but not limited, to the inflammatory cells. For instance, CCL24 was expressed in vascular endothelial cells and CXCL9, previously reported in lining capillaries in the islets (22), was also expressed by PNAd+ vessels within the islets. This finding is of interest because CXCL9 expression has been detected in high endothelial vessels of inflamed lymph nodes (29) but not in pancreatic islets. The combined expression of CXCL9 and CCL21 by endothelial cells may be important for recruitment of CXCR3+ effector T-cells and for recruitment of dendritic cells and memory T-cells expressing CCR7. Increased expression of CCL21 may also contribute to the development of segregated T- and B-cell aggregates reported within prediabetic NOD islets and to the recruitment of CCR7+ monocytes and dendritic cells (12,30).

To date most attempts to interfere with the chemokine pathways in diabetes have relied on the use of neutralizing antibodies to chemokines or chemokine receptors. Neutralization of CXCL10, partially prevents autoimmune disease in the (RIP)-LCMV mouse model (31) and in NOD mice after cyclophosphamide administration (22). CXCL10 DNA vaccination of NOD mice also partially prevents diabetes (32). Neutralization of CCL22 with an antibody causes a significant reduction of CCR4+ T-cells within the pancreatic infiltrates and partially inhibits the development of diabetes in adoptive transfer model in NOD-SCID (14). Furthermore, treatment of NOD mice with a neutralizing anti-CCR5 antibody reduces incidence of diabetes (33). In all of these studies, the individual treatments reduce inflammatory infiltrates, but do not completely block diabetes development, suggesting additional requirements.

To test the hypothesis that diabetes is caused by the combined activities of several chemokines, we used M3, a chemokine binding protein encoded by the mouse herpesvirus 68 (MHV68) that binds several murine and human chemokines with high affinity (34,35). M3 interacts with the N-loop of chemokines and mimics elements of G protein-coupled receptor recognition to block interaction with cognate receptors by a competitive inhibition mechanism (36,37). In vivo, M3 reduces mononuclear cellular responses after MHV68-induced meningitis in mice (38). Systemic expression of M3 reduces intimal hyperplasia subsequent to femoral artery injury (39) and aortic allograft transplantation (40). Finally and perhaps more important in the context of these studies, expression of M3 in transgenic islets inhibits recruitment of leukocytes induced by islet-specific expression of CCL21 (17), CXCL13, and CCL2 (41) and prevents insulitis and diabetes induced by multiple low doses of streptozotocin (18). Here, we show that the scavenging properties of M3 are essential for the reduced inflammation observed in the NOD-M3 transgenic mice. Many of the chemokines upregulated in the NOD model, such as CCL2, CCL3, CCL4 CCL5, and CCL21, bind to M3 with high affinity (34,35).

We suggest that M3 blocks pancreatic autoimmunity by disrupting both the influx and generation of diabetogenic cells. Our results indicate that local M3 expression blocks influx of diabetogenic cells. Adoptive transfer of NOD splenocytes into NOD.SCID and NOD-M3.SCID recipients causes diabetes. However, the course of the disease is delayed in the NOD-M3.SCID mice, suggesting a partial blockade in the recruitment of diabetogenic cells. The failure of M3 to prevent development of diabetes in this context could be due to either the amount or kind of chemokines produced relative to those present in NODM3 islets during development. Experiments addressing these hypotheses are currently underway. Finally, the failure of splenocytes from NOD-M3 mice to transfer disease suggests that either β-cell–specific T-cells are not formed in the NOD-M3 animals or that such cells may be very reduced in number (or poorly activated) and thus incapable of inducing disease.

The activation of naive T-cells requires not only TCR stimulation but also the simultaneous delivery of a costimulatory signal by a specialized antigen-presenting cells in draining lymph nodes. Activation of transgenic, islet-specific CD4+ T-cells (BDC2.5 cells) and diabetogenic CD8+ T-cells occurs in the pancreatic lymph nodes at 3–4 weeks of age (24,27). Interference with priming and diabetes occurs if PPLNs are ablated (42,43) or if important cellular constituents are ablated (44). In this context, dendritic cells are believed to be essential in the initial activation of islet-specific T-cells in PPLNs (27). Both CD11c+CD11b+ and CD11c+CD11b– (or CD11c+CD8+) dendritic cells have been shown to be responsible for presentation of islet antigens in the draining PPLNs (45,46). Recently, Harbers et al. (47) have shown that T-cell proliferation is abolished in dendritic cell–depleted RIP-mOVA/CD11c-DTR mice, and that T-cell proliferation can be reverted when mice are reconstituted with CD11c+ splenic cells, confirming the importance of dendritic cells in islet antigen presentation. Here, we show that NOD-M3 mice have a reduced number of CD11c+CD11b+ cells in both islets and PPLNs at 4 weeks of age. Because dendritic cell migration is highly dependent on chemokines, it is likely that blockade of chemokine function promoted by M3 directly interfered with dendritic cell migration from the blood into islets and draining lymph nodes. Finally, the effects of M3 in our system appear to be local. We have previously shown that M3 is highly expressed by the islets. M3 is detected in the supernatants of transgenic islets cultured in vitro (17,18), and low levels of M3 are present in circulation (41). Thus, the pancreatic levels of expression of M3 are sufficient to block diabetes but do not affect disease development in the salivary and lacrimal glands.

In summary, expression of the chemokine decoy receptor M3 in β-cells prevented development of insulitis and autoimmune diabetes. To date most antagonists targeting single chemokine receptors have not been successful in treating autoimmune diseases in the clinic (48). Our results suggest that chemokine receptor antagonists that can block multiple receptors may be a viable strategy to ameliorate autoimmune diabetes. This concept can be further tested in experimental models using broad-spectrum chemokine antagonists in both prophylactic and therapeutic contexts.


   ACKNOWLEDGMENTS
 
J.S.B. has received funding from the Juvenile Diabetes Research Foundation and National Institutes of Health Grant AI41428. S.A.L. has received funding from the Irene Diamond Fund and National Institutes of Health Grant DK-067381.

We thank Julie Blander, Miriam Merard, Jay Unkeless, Ralph Steinman, and Joshua Farber for reagents and critical comments to the manuscript.


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on 14 November 2007. DOI: 10.2337/db07-1309.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-1309.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication September 14, 2007 and accepted in revised form November 5, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Foulis AK: C.L. Oakley Lecture 1987. The pathogenesis of beta cell destruction in type I (insulin-dependent) diabetes mellitus. J Pathol 152:141–148, 1987[Medline]
  2. Adorini L, Gregori S, Harrison LC: Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 8:31–38, 2002[Medline]
  3. Wicker LS, Miller BJ, Mullen Y: Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35:855–860, 1986[Abstract]
  4. Yagi H, Matsumoto M, Kunimoto K, Kawaguchi J, Makino S, Harada M: Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol 22:2387–2393, 1992[Medline]
  5. Nikolic T, Geutskens SB, van Rooijen N, Drexhage HA, Leenen PJ: Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab Invest 85:487–501, 2005[Medline]
  6. Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW: Absolute requirement of macrophages for the development and activation of β-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice. Diabetes 48:34–42, 1999[Abstract]
  7. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Hollander GA, Piali L: Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8:1414–1420, 2002[Medline]
  8. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L: A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 173:2280–2287, 2004[Abstract/Free Full Text]
  9. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, Bianchi G, Sica A, Peri G, Melzi R, Aldrighetti L, Secchi A, Di Carlo V, Allavena P, Bertuzzi F: Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 51:55–65, 2002[Abstract/Free Full Text]
  10. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, Strieter RM, Cook DN, Delovitch TL: Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 165:1102–1110, 2000[Abstract/Free Full Text]
  11. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL: Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 44:325–332, 2001[Medline]
  12. Bouma G, Coppens JM, Mourits S, Nikolic T, Sozzani S, Drexhage HA, Versnel MA: Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. Eur J Immunol 35:2386–2396, 2005[Medline]
  13. Ploix C, Lo D, Carson MJ: A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity. J Immunol 167:6724–6730, 2001[Abstract/Free Full Text]
  14. Kim SH, Cleary MM, Fox HS, Chantry D, Sarvetnick N: CCR4-bearing T cells participate in autoimmune diabetes. J Clin Invest 110:1675–1686, 2002[Medline]
  15. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV: Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 197:643–656, 2003[Abstract/Free Full Text]
  16. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG: The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 169:2461–2465, 2002[Abstract/Free Full Text]
  17. Jensen KK, Chen SC, Hipkin RW, Wiekowski MT, Schwarz MA, Chou CC, Simas JP, Alcami A, Lira SA: Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J Virol 77:624–630, 2003[Medline]
  18. Martin AP, Alexander-Brett JM, Canasto-Chibuque C, Garin A, Bromberg JS, Fremont DH, Lira SA: The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol 178:4623–4631, 2007[Abstract/Free Full Text]
  19. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D: Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A 93:2260–2263, 1996[Abstract/Free Full Text]
  20. Ikegami H: Animal models of autoimmune polyglandular syndrome. Endocrinol Metab Clin North Am 31:431–439, viii, 2002[Medline]
  21. Kikutani H, Makino S: The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51:285–322, 1992[Medline]
  22. Morimoto J, Yoneyama H, Shimada A, Shigihara T, Yamada S, Oikawa Y, Matsushima K, Saruta T, Narumi S: CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 173:7017–7024, 2004[Abstract/Free Full Text]
  23. Miyagawa J, Hanafusa T, Miyazaki A, Yamada K, Fujino-Kurihara H, Nakajima H, Kono N, Nonaka K, Tochino Y, Tarui S: Ultrastructural and immunocytochemical aspects of lymphocytic submandibulitis in the non-obese diabetic (NOD) mouse. Virchows Arch B Cell Pathol Incl Mol Pathol 51:215–225, 1986[Medline]
  24. Zhang Y, O’Brien B, Trudeau J, Tan R, Santamaria P, Dutz JP: In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol 168:1466–1472, 2002[Abstract/Free Full Text]
  25. Mathis D, Vence L, Benoist C: Beta-cell death during progression to diabetes. Nature 414:792–798, 2001[Medline]
  26. Haskins K, Portas M, Bradley B, Wegmann D, Lafferty K: T-lymphocyte clone specific for pancreatic islet antigen. Diabetes 37:1444–1448, 1988[Abstract]
  27. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D: Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189:331–339, 1999[Abstract/Free Full Text]
  28. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL: IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46:255–266, 2003[Medline]
  29. Janatpour MJ, Hudak S, Sathe M, Sedgwick JD, McEvoy LM: Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med 194:1375–1384, 2001[Abstract/Free Full Text]
  30. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, Romani N, Lira SA: Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol 168:1001–1008, 2002[Abstract/Free Full Text]
  31. Christen U, McGavern DB, Luster AD, von Herrath MG, Oldstone MB: Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 171:6838–6845, 2003[Abstract/Free Full Text]
  32. Shigihara T, Shimada A, Oikawa Y, Yoneyama H, Kanazawa Y, Okubo Y, Matsushima K, Yamato E, Miyazaki J, Kasuga A, Saruta T, Narumi S: CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J Immunol 175:8401–8408, 2005[Abstract/Free Full Text]
  33. Carvalho-Pinto C, Garcia MI, Gomez L, Ballesteros A, Zaballos A, Flores JM, Mellado M, Rodriguez-Frade JM, Balomenos D, Martinez AC: Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur J Immunol 34:548–557, 2004[Medline]
  34. van Berkel V, Barrett J, Tiffany HL, Fremont DH, Murphy PM, McFadden G, Speck SH, Virgin HI: Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 74:6741–6747, 2000[Abstract/Free Full Text]
  35. Parry CM, Simas JP, Smith VP, Stewart CA, Minson AC, Efstathiou S, Alcami A: A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 191:573–578, 2000[Abstract/Free Full Text]
  36. Alexander JM, Nelson CA, van Berkel V, Lau EK, Studts JM, Brett TJ, Speck SH, Handel TM, Virgin HW, Fremont DH: Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 111:343–356, 2002[Medline]
  37. Webb LM, Clark-Lewis I, Alcami A: The gammaherpesvirus chemokine binding protein binds to the N terminus of CXCL8. J Virol 77:8588–8592, 2003[Abstract/Free Full Text]
  38. van Berkel V, Levine B, Kapadia SB, Goldman JE, Speck SH, Virgin HWT: Critical role for a high-affinity chemokine-binding protein in gamma-herpesvirus-induced lethal meningitis. J Clin Invest 109:905–914, 2002[Medline]
  39. Pyo R, Jensen KK, Wiekowski MT, Manfra D, Alcami A, Taubman MB, Lira SA: Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. Am J Pathol 164:2289–2297, 2004[Abstract/Free Full Text]
  40. Liu L, Dai E, Miller L, Seet B, Lalani A, Macauley C, Li X, Virgin HW, Bunce C, Turner P, Moyer R, McFadden G, Lucas A: Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 77:1652–1660, 2004[Medline]
  41. Martin AP, Canasto-Chibuque C, Shang L, Rollins BJ, Lira SA: The chemokine decoy receptor M3 blocks CC chemokine ligand 2 and CXC chemokine ligand 13 function in vivo. J Immunol 177:7296–7302, 2006[Abstract/Free Full Text]
  42. Levisetti MG, Suri A, Frederick K, Unanue ER: Absence of lymph nodes in NOD mice treated with lymphotoxin-β receptor immunoglobulin protects from diabetes. Diabetes 53:3115–3119, 2004[Abstract/Free Full Text]
  43. Gagnerault MC, Luan JJ, Lotton C, Lepault F: Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med 196:369–377, 2002[Abstract/Free Full Text]
  44. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW: The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 189:347–358, 1999[Abstract/Free Full Text]
  45. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K: The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195:1289–1302, 2002[Abstract/Free Full Text]
  46. Turley S, Poirot L, Hattori M, Benoist C, Mathis D: Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198:1527–1537, 2003[Abstract/Free Full Text]
  47. Harbers SO, Crocker A, Catalano G, D’Agati V, Jung S, Desai DD, Clynes R: Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117:1361–1369, 2007[Medline]
  48. Wells TN, Power CA, Shaw JP, Proudfoot AE: Chemokine blockers: therapeutics in the making? Trends Pharmacol Sci 27:41–47, 2006[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-1309v1
57/2/387    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, A. P.
Right arrow Articles by Lira, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, A. P.
Right arrow Articles by Lira, S. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum